Hussman Strategic Advisors Inc. purchased a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,250 shares of the company’s stock, valued at approximately $624,000.

A number of other institutional investors also recently made changes to their positions in the stock. ARK Investment Management LLC grew its holdings in Crispr Therapeutics by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock worth $180,074,000 after buying an additional 174,495 shares in the last quarter. Nikko Asset Management Americas Inc. grew its holdings in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics during the third quarter worth $21,167,000. Global Thematic Partners LLC grew its holdings in Crispr Therapeutics by 1.7% during the fourth quarter. Global Thematic Partners LLC now owns 350,386 shares of the company’s stock worth $21,340,000 after buying an additional 5,764 shares in the last quarter. Finally, Morgan Stanley grew its holdings in Crispr Therapeutics by 6.1% during the second quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after buying an additional 16,361 shares in the last quarter. Institutional investors and hedge funds own 50.01% of the company’s stock.

CRSP stock opened at $52.71 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -114.59 and a beta of 3.26. Crispr Therapeutics AG has a fifty-two week low of $29.34 and a fifty-two week high of $74.00. The stock has a fifty day moving average of $60.27 and a 200-day moving average of $52.74.

A number of research analysts have issued reports on CRSP shares. Goldman Sachs Group upped their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research note on Thursday, January 30th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, Roth Capital upped their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $75.95.

In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. Insiders have sold a total of 48,618 shares of company stock valued at $3,230,760 in the last quarter. 21.40% of the stock is owned by corporate insiders.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What is the price-sales ratio?

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link